A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer

An Open Label Study to Assess the Effect of First-line Treatment With Avastin in Combination With Docetaxel and Cisplatin on Progression-free Survival in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer

This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer. Patients received Avastin 15 mg/kg intravenously (IV), docetaxel 75 mg/m^2, and cisplatin 75 mg/m^2 on Day 1 of each 3-week cycle for a maximum of 6 cycles.

Inclusion Criteria:

• Adult patients, ≥ 18 years of age.
• Stage IIIb or IV non-small cell lung cancer.
• Chemotherapy-naive.

Exclusion Criteria:

• Previous treatment for non-small cell lung cancer.
• Previous malignant tumor within last 5 years, except for basal cell skin cancer or preinvasive cervical cancer.
• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to start of study.
• Recent or current chronic treatment with aspirin (> 325 mg/day).